XML 103 R72.htm IDEA: XBRL DOCUMENT v3.25.4
REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Dec. 03, 2024
USD ($)
performanceObligation
Dec. 12, 2021
USD ($)
Jul. 31, 2025
USD ($)
Feb. 28, 2025
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2021
USD ($)
Disaggregation of Revenue [Line Items]              
Total revenue         $ 244,061 $ 3,550  
Accounts receivable         3,567 2,742  
License revenue              
Disaggregation of Revenue [Line Items]              
Total revenue         205,355 3,000  
Service revenue              
Disaggregation of Revenue [Line Items]              
Total revenue         38,500    
Takeda Pharmaceuticals U.S.A., Inc. | License revenue              
Disaggregation of Revenue [Line Items]              
Upfront license fee $ 200,000            
Reimbursement from limited partnership investment 51,400            
Takeda Pharmaceuticals U.S.A., Inc. | License and Know-How              
Disaggregation of Revenue [Line Items]              
Upfront license fee 195,400            
Takeda Pharmaceuticals U.S.A., Inc. | Transition Services              
Disaggregation of Revenue [Line Items]              
Upfront license fee $ 56,100            
Hansoh Agreement | Hansoh Shanghai Healthtech Co Ltd              
Disaggregation of Revenue [Line Items]              
Total revenue   $ 18,000          
Revenue, remaining performance obligation, development milestones, variable consideration         23,500    
Revenue, remaining performance obligation, sales milestones, variable consideration amount         $ 144,000    
Upfront license fee           3,000 $ 20,000
Withholding taxes from upfront fee           300 $ 2,000
License Agreement | Maximum              
Disaggregation of Revenue [Line Items]              
Term of the TSA fifteen            
License Agreement | Minimum              
Disaggregation of Revenue [Line Items]              
Term of the TSA six            
License Agreement | Hansoh Shanghai Healthtech Co Ltd              
Disaggregation of Revenue [Line Items]              
Expiration period         10 years    
License Agreement | Takeda Pharmaceuticals U.S.A., Inc.              
Disaggregation of Revenue [Line Items]              
Total revenue     $ 10,000   $ 10,000    
Expiration period         10 years    
License agreement upfront fee       $ 200,000      
Potential milestone, development based milestones         $ 80,000    
Potential milestone payments, commercial-based milestones         280,000    
Potential milestone payments, sales-based milestones $ 740,000            
Number of performance obligations | performanceObligation 2            
Accounts receivable         3,600 0  
Tech Transfer Agreement | Manufacturing Technology Transfer Agreement              
Disaggregation of Revenue [Line Items]              
Service revenue         100 100  
Supply Agreement | Clinical Product Supply Agreement              
Disaggregation of Revenue [Line Items]              
Upfront license fee         $ 100 $ 400